Amryt Pharma posts €1.35m revenue

Positive contributions from acquisitions helped Dublin-listed orphan drug firm Amryt Pharma generate revenues of just over €1.35m in 2016, its first year as a commercial entity.

The company — which grew out of a reverse takeover of Dublin-based investment firm Fastnet Equity — yesterday reported an operating loss of €7.7m for the year.

Amryt is currently in clinical trial stage with its headline prospective drug, which is aimed at treating rare skin condition Epidermolysis bullosa; and pre-clinical stage with another compound that could treat rare growth disorder acromegaly.